SpringerLink
Log in

Dramatic response to alectinib in a lung adenocarcinoma patient harboring a Novel SSFA2-ALK fusion

  • Letters to the Editor
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

ALK (anaplastic lymphoma kinase) gene rearrangements have been reported in 3–5% of NSCLC patients. Different ALK fusion forms can mediate different downstream signaling pathways and may exhibit different sensitivities to ALK tyrosine kinase inhibitors (TKIs). To identify more fusion partners that are sensitive to ALK-TKIs, we present a case of 46-year-old woman with stage IV lung adenocarcinoma. NGS panel analysis suggested that a novel SSFA2-ALK fusion was identified in this patient. Moreover, this fusion was validated through IHC (VENTANA ALK (D5F3) antibody) and FISH (ZytoLight ALK Break Apart FISH Probe). Importantly, to the best of our knowledge, there is no report about SSFA2-ALK fusion in solid cancers. Moreover, the patient achieved an admirable response to alectinib, with a clinical evaluation of complete response (CR). In summary, our findings expand the spectrum of ALK fusion patterns and provide robust evidence for the precise administration of alectinib in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Availability of data and materials

All data generated or analyzed during this study are included in this article.

References

  1. Gainor JF, Varghese AM, Ou S-HI et al (2013) ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 19:4273–4281. https://doi.org/10.1158/1078-0432.CCR-13-0318

    Article  CAS  Google Scholar 

  2. Ou SI, Zhu VW, Nagasaka M (2020) Catalog of 5’ Fusion Partners in ALK-positive NSCLC Circa 2020. JTO Clin Res Rep 1:100015. https://doi.org/10.1016/j.jtocrr.2020.100015

    Article  PubMed  PubMed Central  Google Scholar 

  3. Peters S, Camidge DR, Shaw AT et al (2017) Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med 377:829–838. https://doi.org/10.1056/NEJMoa1704795

    Article  CAS  PubMed  Google Scholar 

  4. Lei YY, Yang JJ, Zhang XC et al (2016) Anaplastic Lymphoma Kinase Variants and the Percentage of ALK-Positive Tumor Cells and the Efficacy of Crizotinib in Advanced NSCLC. Clin Lung Cancer 17:223–231. https://doi.org/10.1016/j.cllc.2015.09.002

    Article  CAS  PubMed  Google Scholar 

  5. Kang J, Zhang XC, Chen HJ et al (2020) Complex ALK Fusions Are Associated With Better Prognosis in Advanced Non-Small Cell Lung Cancer. Front Oncol 10:596937. https://doi.org/10.3389/fonc.2020.596937

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank Dr. Chuang Qi, Dr. Wanglong Deng and Dr. Guanghua Lu, and Mr. Ran Ding from Jiangsu Simcere Diagnostics for their kind assistance.

Author information

Authors and Affiliations

  1. Department of Oncology, Shanxi Provincial People’s Hospital, Taiyuan, 030012, China

    **nyi Lin

  2. Pulmonary and Critical Care Medicine, Shanxi Provincial People’s Hospital, Shanxi, China

    **aojuan Yang & Mei He

  3. The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd, Nan**g Simcere Medical Laboratory Science Co., LtdThe State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Building 5, No. 699-18 Xuanwu Avenue, Xuanwu District, Nan**g, Jiangsu Province, China

    Yuan Tan & Qianqian Duan

Authors
  1. **nyi Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. **aojuan Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuan Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Qianqian Duan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mei He
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Yuan Tan, **ny Lin and QianQ Duan prepared the manuscript and the literature search; Mei H reviewed and edited the manuscript; **ny Lin and **aoJ Y treated and observed the patient; **aoJ Y performed the histopathological, immunohistochemical examinations. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Mei He.

Ethics declarations

Ethics approval and consent to participate

Authors’ institution does not require ethical approval for publication of a single case report. Written informed consent was obtained from the patient.

Consent for publication/Informed consent

Written informed consent was obtained from the patient for publication of the Case Report and any accompanying images.

Conflicts of interest/Competing interest

The authors declare that they have no competing interest.

Research involving human participants and/or animals

All procedures performed in this case report involving human participants were in accordance with the ethical standards of the Shanxi Provincial People’s Hospital and with the Helsinki declaration and its later amendments or comparable ethical standards.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lin, X., Yang, X., Tan, Y. et al. Dramatic response to alectinib in a lung adenocarcinoma patient harboring a Novel SSFA2-ALK fusion. Invest New Drugs 40, 1160–1163 (2022). https://doi.org/10.1007/s10637-022-01260-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-022-01260-4

Keywords

Search

Navigation